Penicillamine: the treatment of first choice for patients with Wilson's disease.
Walshe
J M
JM
The Reta Lila Weston Institute of Neurological Studies, University College, London, UK.
D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*
D002614:Chelating Agents; D010396:Penicillamine